OptiNose

OptiNose EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of OptiNose (OPTN) as of Nov 11, 2026 is -22.97. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -5.26 — a change of 336.72% (lower).

EV/EBIT

-22.97

YoY

336.72%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of OptiNose is 2024 -22.97 . EV/EBIT (Enterprise Value to EBIT) of OptiNose was 2023 -5.26 . It decreases by 336.72% lower compared to the previous year.

The OptiNose EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-1.02 USD
Jan 1, 2020
-1.11 USD
Jan 1, 2021
-1.46 USD
Jan 1, 2022
-1.74 USD
Jan 1, 2023
-5.26 USD
Jan 1, 2024
-22.97 USD
Jan 1, 2025 (e)
-1.93 USD
Jan 1, 2026 (e)
-1.70 USD
The OptiNose EV/EBIT history
YEAREV/EBITYoY
est-1.70-11.92%
est-1.93-91.60%
-22.97+336.72%
-5.26+202.43%
-1.74+18.88%
-1.46+31.26%
-1.11+9.61%
-1.02+4.85%
-0.97-51.59%
-2.00-152.17%
3.84-210.89%
-3.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides OptiNose's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates OptiNose's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots OptiNose's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if OptiNose grows earnings faster than its peers.

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiNose stock

EV/EBIT (Enterprise Value to EBIT) of OptiNose is -22.97 in 2024.

EV/EBIT (Enterprise Value to EBIT) of OptiNose changed from -5.26 to -22.97, representing a 336.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) OptiNose since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s OptiNose with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OptiNose

All Key Metrics — OptiNose